JP2023549098A5 - - Google Patents

Info

Publication number
JP2023549098A5
JP2023549098A5 JP2023526375A JP2023526375A JP2023549098A5 JP 2023549098 A5 JP2023549098 A5 JP 2023549098A5 JP 2023526375 A JP2023526375 A JP 2023526375A JP 2023526375 A JP2023526375 A JP 2023526375A JP 2023549098 A5 JP2023549098 A5 JP 2023549098A5
Authority
JP
Japan
Prior art keywords
cell
receptor
cells
car
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023526375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549098A (ja
JP7863553B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/072255 external-priority patent/WO2022099297A1/en
Publication of JP2023549098A publication Critical patent/JP2023549098A/ja
Publication of JP2023549098A5 publication Critical patent/JP2023549098A5/ja
Priority to JP2026079789A priority Critical patent/JP2026121415A/ja
Application granted granted Critical
Publication of JP7863553B2 publication Critical patent/JP7863553B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023526375A 2020-11-04 2021-11-04 固形腫瘍を標的とする多重操作されたiPSC及び免疫エフェクター細胞 Active JP7863553B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026079789A JP2026121415A (ja) 2020-11-04 2026-05-11 固形腫瘍を標的とする多重操作されたiPSC及び免疫エフェクター細胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063109842P 2020-11-04 2020-11-04
US63/109,842 2020-11-04
US202163228490P 2021-08-02 2021-08-02
US63/228,490 2021-08-02
PCT/US2021/072255 WO2022099297A1 (en) 2020-11-04 2021-11-04 Multiplexed engineered ipsc and immune effector cells targeting solid tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026079789A Division JP2026121415A (ja) 2020-11-04 2026-05-11 固形腫瘍を標的とする多重操作されたiPSC及び免疫エフェクター細胞

Publications (3)

Publication Number Publication Date
JP2023549098A JP2023549098A (ja) 2023-11-22
JP2023549098A5 true JP2023549098A5 (cg-RX-API-DMAC7.html) 2024-11-13
JP7863553B2 JP7863553B2 (ja) 2026-05-21

Family

ID=81456848

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023526375A Active JP7863553B2 (ja) 2020-11-04 2021-11-04 固形腫瘍を標的とする多重操作されたiPSC及び免疫エフェクター細胞
JP2026079789A Pending JP2026121415A (ja) 2020-11-04 2026-05-11 固形腫瘍を標的とする多重操作されたiPSC及び免疫エフェクター細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026079789A Pending JP2026121415A (ja) 2020-11-04 2026-05-11 固形腫瘍を標的とする多重操作されたiPSC及び免疫エフェクター細胞

Country Status (9)

Country Link
US (1) US20230381235A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240834A4 (cg-RX-API-DMAC7.html)
JP (2) JP7863553B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230096110A (cg-RX-API-DMAC7.html)
AU (1) AU2021376382A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196555A1 (cg-RX-API-DMAC7.html)
IL (1) IL302481A (cg-RX-API-DMAC7.html)
MX (1) MX2023004326A (cg-RX-API-DMAC7.html)
WO (1) WO2022099297A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
US20230288405A1 (en) * 2022-01-20 2023-09-14 3T Biosciences, Inc. T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
JP2025520225A (ja) * 2022-05-18 2025-07-02 シアトル チルドレンズ ホスピタル ディー/ビー/エイ シアトル チルドレンズ リサーチ インスティテュート 多重特異性結合剤の製造および/または送達
GB202208545D0 (en) * 2022-06-10 2022-07-27 Adaptimmune Ltd Production of immune cells
EP4780945A1 (en) * 2023-09-20 2026-07-29 Kure.AI, Inc. Methods and reagents to improve cell therapy with the creation of novel car-targeting mr1 protein
WO2025067318A1 (zh) * 2023-09-28 2025-04-03 沛尔生技医药股份有限公司 具有细胞内信号传导结构域及自然杀伤蛋白30跨膜结构域的核酸分子及包含其的嵌合抗原受体
GB202318950D0 (en) * 2023-12-12 2024-01-24 Adaptimmune Ltd Production of immune cells
WO2026019829A1 (en) * 2024-07-15 2026-01-22 A2 Biotherapeutics, Inc. Compositions and methods for stimulating t cells used in cell therapy with a bispecific bridging molecule

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108456247A (zh) * 2017-02-20 2018-08-28 上海恒润达生生物科技有限公司 靶向ny-eso-1的t细胞受体及其用途
GB201717578D0 (en) 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
CA3090793C (en) * 2018-02-16 2024-10-08 Kite Pharma, Inc. MODIFIED MULTIPOTENTED STEM CELLS, AND METHODS OF PREPARATION AND USE
KR102892744B1 (ko) * 2018-04-19 2025-11-28 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Mage-b2 특이성을 갖는 t 세포 수용체 및 이의 용도
EP3632460A1 (en) * 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
CN113906133A (zh) 2019-04-11 2022-01-07 菲特治疗公司 工程改造的iPSC和免疫效应细胞中的CD3重建
US20220213198A1 (en) * 2019-05-22 2022-07-07 The Council Of The Queensland Institute Of Medical Research Method of treatment

Similar Documents

Publication Publication Date Title
JP2022550899A5 (cg-RX-API-DMAC7.html)
JP2021505131A5 (cg-RX-API-DMAC7.html)
JP2022541441A5 (cg-RX-API-DMAC7.html)
JP2022548943A5 (cg-RX-API-DMAC7.html)
JP2023548467A5 (cg-RX-API-DMAC7.html)
JP2022510207A5 (cg-RX-API-DMAC7.html)
JP2023530704A5 (cg-RX-API-DMAC7.html)
JP7623020B2 (ja) 同種異系移植のための操作された免疫細胞
JP2023548829A5 (cg-RX-API-DMAC7.html)
JP2021519061A5 (cg-RX-API-DMAC7.html)
JP7767502B2 (ja) Nk阻害性分子を発現する遺伝子改変免疫細胞とその使用
JP2023505206A5 (cg-RX-API-DMAC7.html)
JP2023545992A5 (cg-RX-API-DMAC7.html)
JP2024518011A5 (cg-RX-API-DMAC7.html)
CN114015656A (zh) 用于同种异体移植的工程化免疫细胞
EP4194472A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
WO2015028444A1 (en) Anti cd30 chimeric antigen receptor and its use
KR20230137923A (ko) 신규한 키메라 항원 수용체 및 이의 용도
US20230210905A1 (en) T cell-antigen coupler with various construct optimizations
KR20210126008A (ko) 세포 면역 치료의 조합
US20220133792A1 (en) Signaling platforms for chimeric antigen receptor t cells
KR20210018838A (ko) 유전자 조작된 세포 및 응용
JP2024515920A5 (cg-RX-API-DMAC7.html)
JP2024526237A5 (cg-RX-API-DMAC7.html)
CN115873801A (zh) 工程化免疫细胞及其用途